Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...
Eli Lilly's Kisunla receives Japanese approval for the treatment of early symptomatic Alzheimer's disease: Indianapolis Wednesday, September 25, 2024, 09:00 Hrs [IST] The Ministry ...